Tislelizumab (Tislelizumab, BGB-A317)

Immunotherapy

US Experimental EU Experimental ES med_spain_not_available IV 58 Clinical Trials
PD-1

Description

Tislelizumab is under investigation for the treatment of colorectal cancer and has shown promise in clinical trials as a single agent or in combination with other immunotherapies. Its use is currently experimental and not approved by the FDA for CCR, but it may be considered in certain clinical trial settings.

Mechanism of Action

Tislelizumab is a humanized IgG4 monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, thus inhibiting tumor-mediated T-cell suppression.

Molecular Targets

Side Effects

Fatigue; nausea; diarrhea; constipation; decreased appetite; rash; pruritus; hypothyroidism; hyperthyroidism; colitis; pneumonitis; hepatitis; nephritis; adrenal insufficiency

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06722183 med_phase_prefix2
Recruiting
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
Germany
NCT07244705 med_phase_prefix1
Recruiting
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Australia, Taiwan
NCT06856837 med_phase_prefix2
Recruiting
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Austria, Germany
NCT07136077 med_phase_prefix2
Recruiting
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
United States
NCT06940388 med_phase_prefix2
Recruiting
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
Germany, Israel
NCT06332274 med_phase_prefix3
Recruiting
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
France
View all 58 clinical trials →

Quick Info

Brand NameTislelizumab, BGB-A317
CategoryImmunotherapy
US StatusExperimental
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_available
AdministrationIV
Clinical Trials58
View Clinical Trials Back to Drug Glossary

Related Medications

Pembrolizumab
Immunotherapy
159 trials
Nivolumab
Immunotherapy
105 trials
Sintilimab
Immunotherapy
33 trials
Cadonilimab
Immunotherapy
19 trials
Serplulimab
Immunotherapy
17 trials
Tori
Immunotherapy
15 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.